Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Accounts Payables (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Accounts Payables for 16 consecutive years, with $1.2 million as the latest value for Q1 2026.

  • Quarterly Accounts Payables rose 147.47% to $1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Jan 2026, up 147.47% year-over-year, with the annual reading at $399204.0 for FY2025, 45.7% down from the prior year.
  • Accounts Payables for Q1 2026 was $1.2 million at PharmaCyte Biotech, up from $1.0 million in the prior quarter.
  • The five-year high for Accounts Payables was $1.2 million in Q1 2026, with the low at $3015.0 in Q1 2022.
  • Average Accounts Payables over 5 years is $514112.5, with a median of $484198.0 recorded in 2024.
  • Peak annual rise in Accounts Payables hit 14690.55% in 2023, while the deepest fall reached 85.35% in 2023.
  • Over 5 years, Accounts Payables stood at $861276.0 in 2022, then tumbled by 85.35% to $126163.0 in 2023, then skyrocketed by 176.31% to $348595.0 in 2024, then soared by 192.99% to $1.0 million in 2025, then increased by 17.5% to $1.2 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $1.2 million, $1.0 million, and $465209.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.